Medicare Intermediary Manual Part 3 Claims Process

Department of Health and Human Services (DHHS) HEALTH CARE FINANCING ADMINISTRATION (HCFA)

Part 3 - Claims Process

Transmittal 1805 Date: AUGUST 29, 2000

CHANGE REQUEST 1002

HEADER SECTION NUMBERS

PAGES TO INSERT

PAGES TO DELETE

Table of Contents - Chapter VII 3614.1 - 3614.4

6-1 - 6-2 (2 pp.) 6-136.3 - 6-136.5 (3 pp.) 6-1 - 6-2 (2 pp.) 6-136.3 - 6-136.4 (2 pp.)

NEW/REVISED MATERIAL--EFFECTIVE DATE: 10/01/00 IMPLEMENTATION DATE: 10/01/00

Section 3614, Stem Cell Transplantation, provides claims processing instructions for the coverage of stem cell transplants. It has been updated to include both the covered and noncovered diagnosis and procedure codes for allogeneic and autologous stem cell transplants. In addition to clarifying the current coverage as described in the Coverage Issues Manual §35-30.1, effective 10/01/2000, autologous stem cell transplantation will also be covered for Medicare beneficiaries with multiple myeloma, less than age 78 who have Durie-Salmon stage II or III newly diagnosed or responsive multiple myeloma with adequate cardiac, renal, pulmonary, and hepatic function. Multiple rounds of autologous stem cell transplantation (known as tandem transplantation) will, however, remain non-covered. The Coverage Issues Manual also includes nonprimary amyloidosis as a noncovered condition and primary (AL) amyloidosis as a noncovered condition for Medicare beneficiaries age 64 or older.

<u>Section 3614.1, Allogeneic Stem Cell Transplantation</u>, provides background, coverage, and coding information on Allogeneic stem cell transplantation.

<u>Section 3614.2, Autologous Stem Cell Transplantation</u>, provides background, coverage, and coding information on Autologous stem cell transplantation.

Section 3614.3, Acquisition Costs, provides information on stem cell acquisition charges.

Please notify your providers of these changes.

These instructions should be implemented within your current operating budget.

DISCLAIMER: The revision date and transmittal number only apply to the redlined material. All other material was previously published in the manual and is only being reprinted.

HCFA-Pub. 13-3

CHAPTER VII BILL REVIEW

	Section
General Requirements	3600
General Requirements Claims Processing Timeliness Time Limitation for Filing Provider Claims	3600.1
Time Limitation for Filing Provider Claims	3600.2
Reviewing Bills for Services After Suspension, Termination, Expiration, or Cancellation of Provider Agreement, or After a SNF is Denied Payment for	
New Admissions	3600.3
Change of Intermediary	3600.4
Multiple Provider Numbers or Changes in Provider Number	3600.5
Electronic Data Interchange (EDI)	
Electronic Data Interchange Security, Privacy, Audit and Legal Issues	3601
Electronic Data Interchange Security, Privacy, Audit and Legal Issues	3601.1
EDI Audit Trails	3601.2
EDI Audit Trails	
Network Services	3601.3
Electronic Data Interchange (EDI) Enrollment Form Information Regarding the Release of Medicare Eligibility Data.	3601.4
Information Regarding the Release of Medicare Eligibility Data	3601.5
New Policy on Releasing Eligibility Data	3601.6
Advise Your Providers and Network Service Vendors	3001./
Network Service Agreement	2602
Electronic Media Claims (EMC).	3002 3602 1
Requirements for Submission of EMC Data	3602.1
File Specifications, Records Specifications, and Data Element Definitions	3002.2
for EMC Bills	3602.3
Paper Bill.	
Medicare Intermediary Standard Paper Remittance	3602.1
Medicare Intermediary Standard Paper Remittance Electronic UB-92 Change Request Procedures	3602.6
Medicare Standard Electronic Remittance.	3602.7
Medicare Standard Electronic Remittance	3602.8
Frequency of Billing.	3603
Frequency of Billing	
Inpatient Stay	3603.1
Need to Reprocess Inpatient Claims In-Sequence	3603.2
Form HCFA-1450	
Review of Form HCFA-1450 for Inpatient and Outpatient Bills	3604
Incomplete and Invalid Claims	3605
Claims Processing Terminology Handling Incomplete and Invalid Claims.	3605.1
Handling Incomplete and Invalid Claims.	3605.2

Data Element Requirements Matrix	3605.3
Form HCFA-1450 Consistency Edits	3606
Hospital Inpatient Bills-General	
Charges to Beneficiaries by PPS Hospitals	
Payment for Ancillary Services	
Outpatient Services Treated as Inpatient Services	
Admission Prior to and Discharge After PPS Implementation Date	
Transfers Between Hospitals	
Split Bills	3610.6
Outliers	
Adjustment Bills	

Rev.1805

CHAPTER VII BILL REVIEW

	Section
Waiver of Liability	3610.9
Effects of Guarantee of Payment	3610.10
Remittance Advice to the Hospital	3610.11
Noncovered Admission Followed by Covered Level of Care	3610.12
Repeat Admissions and Leave of Absence	3610.14
Repeat Admissions and Leave of Absence	
Low Income Patients	3610.15
Rural Referral Centers (RRCs)	3610.16
Criteria and Payment for Sole Community Hospitals and for Medicare	
Dependent Hospitals	3610.17
Dependent Hospitals Payment for Blood Clotting Factor Administered to Hemophilia Inpatients	3610.18
Medicare Rural Hospital Flexibility Program. Grandfathering of Existing Facilities	3610.19
Grandfathering of Existing Facilities	3610.20
Requirements for CAH Services and CAH Long-term Care Services	3610.21
Payment for Services Furnished by a CAH	3610.22
Requirements for CAH Services and CAH Long-term Care Services	3610.23
Review of Form HCFA-1450 for the Inpatient	3610.24
Hospital Capital Payments Under PPS	3611
Federal Rate	3611.1
Hold Harmless Payments	3611.2
Blended Payments	3611.3
Capital Payments in Puerto Rico	3611.4
Old and New Capital	
New Hospitals .	3611.6
Capital PPS Exception Payment	
Outliers	
Admission Prior to and Discharge After Capital PPS Implementation Date	3611.9
Market Basket Update	3011.10
Kidney Transplant - General	3012
The Standard Kidney Acquisition Charge	3012.1 2612.2
Charges for Kidney Acquisition Services	3612.2
Notifying Carriers	3612.3
Heart Transplants	3012. 4
Notifying Carriers	
Stem Cell Transplantation	
Allogeneic Stem Cell Transplantation	3614 1
Autologous Stem Cell Transplantation	3614.1
Acquisition Cost	
Notifying Carriers	3614.4
Liver Transplants	3615
Standard Liver Acquisition Charge	3615.1
Billing for Liver Transplant and Acquisition Services	3615.2
Charges for Liver Acquisition Services	3615.3
Notifying Carriers	
List of Approved Liver Transplant Center	3615.5
Prostate Cancer Screening Tests and Procedures	3616
Payments of Nonphysician Services Hospitals Obtain for Hospital Inpatients	3618
Determining Covered/Noncovered Days and Charges	3620
Spell of Illness	3622
Processing No-Payment Bills	3624
Processing Provider Liable Inpatient BillsLack of Medical Necessity or	
Care is Custodial	3625

6-2 Rev.1805

3614. STEM CELL TRANSPLANTATION

Stem cell transplantation is a process in which stem cells are harvested from either a patient's or donor's bone marrow or peripheral blood for intravenous infusion. The transplant can be used to effect hematopoietic reconstitution following severely myelotoxic doses of chemotherapy (HDCT) and/or radiotherapy used to treat various malignancies. Allogeneic stem cell transplant may also be used to restore function in recipients having an inherited or acquired deficiency or defect.

Allogeneic and autologous stem cell transplants are covered under Medicare for specific diagnoses. Effective 10/01/90, these cases are assigned DRG 481, Bone Marrow Transplant.

See Coverage Issues Manual, §35-30.1 for a complete description of covered and noncovered conditions.

The Outpatient Code Editor (OCE) will edit stem cell transplant procedure codes against diagnosis codes to determine which cases may meet the specified coverage criteria. Those cases with a diagnosis code for a covered condition will pass (as covered) the OCE noncovered procedure edit. Pay any claims that pass the OCE for eligible beneficiaries. When a stem cell transplant case is selected for review based on the random selection of beneficiaries, the PRO will review the case on a post-payment basis to assure proper coverage decisions. Stem Cell transplants are typically performed in the outpatient setting. Should complications occur, then the procedure would be performed on an inpatient basis. When performed on an inpatient basis, the claim would go through the Medicare Code Editor (MCE), instead of the OCE.

The OCE/MCE classifies procedure code 41.00 (Bone marrow transplant, not otherwise specified) as noncovered. Return the claim to the provider for a more specific procedure code.

3614.1 <u>Allogeneic Stem Cell Transplantation</u>.--

A. <u>General</u>.--Allogeneic stem cell transplantation (ICD-9-CM Procedure Codes 41.02, 41.03, 41.05, and 41.08, CPT-4 Code 38240) is a procedure in which a portion of a healthy donor's stem cells is obtained and prepared for intravenous infusion to restore normal hematopoietic function in recipients having an inherited or acquired hematopoietic deficiency or defect.

Expenses incurred by a donor are a covered benefit to the recipient/beneficiary but, except for physician services, are not paid separately. Services to the donor include physician services, hospital care in connection with screening the stem cell, and ordinary follow-up care.

B. Covered Conditions.--

- 1. Effective for services performed on or after August 1, 1978:
- o For the treatment of leukemia, leukemia in remission (ICD-9-CM codes 204.00 through 208.91), or aplastic anemia (ICD-9-CM codes 284.0 through 284.9) when it is reasonable and necessary; and
 - 2. Effective for services performed on or after June 3, 1985:
- o For the treatment of severe combined immunodeficiency disease (SCID) (ICD-9-CM code 279.2), and for the treatment of Wiskott Aldrich syndrome (ICD-9-CM 279.12).

C. Noncovered Conditions.--

1. Effective for services performed on or after May 24, 1996:

- o Allogeneic stem cell transplantation is not covered as treatment for multiple myeloma (ICD-9-CM codes 203.00 and 203.01).
- **NOTE**: Coverage for conditions other than these specifically designated as covered or noncovered in this section or §35-30.1 of the CIM are left to individual intermediary's discretion.
- D. <u>Billing for Allogeneic Stem Cell Transplants</u>.--The donor is covered for medically necessary inpatient hospital days of care in connection with the stem cell transplant operation. Expenses incurred for complications are covered only if they are directly and immediately attributable to the stem cell donation procedure.

Hospital services furnished in connection with a stem cell transplant are covered under Part A. Charges are reported on the hospital billing form submitted for the recipient. Days of care used by the donor are not charged against the recipient's utilization record. For purposes of cost reporting, include the covered donor days and charges as Medicare days and charges. Physicians' services are billed under Part B to the carrier, on the account of the recipient, and are paid at 80 percent of reasonable charges.

Charges for the transplant itself will generally be shown in revenue center code 362, although selection of the cost center is up to the hospital.

3614.2 <u>Autologous Stem Cell Transplantation</u>.--

A. <u>General</u>.--Autologous stem cell transplantation (ICD-9-CM procedure code 41.01, 41.04, 41.07, and 41.09 and CPT-4 code 38241) is a technique for restoring stem cells using the patient's own previously stored cells.

B. <u>Covered Conditions</u>.--

- 1. Effective for services performed on or after April 28, 1989:
- o Acute leukemia in remission (ICD-9-CM codes 204.01, lymphoid; 205.01, myeloid; 206.01, monocytic; 207.01, acute erythremia and erythroleukemia; and 208.01 unspecified cell type) patients who have a high probability of relapse and who have no human leucocyte antigens (HLA)-matched;
- o Resistant non-Hodgkin's lymphomas (ICD-9-CM codes 200.00-200.08, 200.10-200.18, 200.20-200.28, 200.80-200.88, 202.00-202.08, 202.80-202.88, and 202.90-202.98) or those presenting with poor prognostic features following an initial response;
- o Recurrent or refractory neuroblastoma (see ICD-9-CM Neoplasm by site, malignant); or
- o Advanced Hodgkin's disease (ICD-9-CM codes 201.00-201.98) patients who have failed conventional therapy and have no HLA-matched donor.
 - 2. Effective for services performed on or after 10/01/00:
- o Multiple myeloma (ICD-9-CM code 203.00 and 238.6), for beneficiaries less than age 78, who have Durie-Salmon stage II or III newly diagnosed or responsive multiple myeloma and adequate cardiac, renal, pulmonary and hepatic functioning. Multiple rounds of autologous stem cell transplantation (known as tandem transplantation) will, however, remain non-covered.

6-136.4 Rev.1805

- o Primary amyloidosis (ICD-9-CM code 277.3), for beneficiaries under the age of 64, **coverage is at the intermediary's discretion.**
- C. <u>Noncovered Conditions</u>.--Insufficient data exist to establish definite conclusions regarding the efficacy of autologous stem cell transplantation for the following conditions:
- o Acute leukemia not in remission (ICD-9-CM codes 204.00, 205.00, 206.00, 207.00 and 208.00);
 - o Chronic granulocytic leukemia (ICD-9-CM codes 205.10 and 205.11);
 - o Solid tumors (other than neuroblastoma) (ICD-9-CM codes 140.0-199.1);
 - o Multiple myeloma (ICD-9-CM code 203.00 and 238.6), through 9/30/00
- o Tandem transplantation (multiple rounds of autologous stem cell transplantation) for patients with multiple myeloma (ICD-9-CM code 203.00 and 238.6)
 - o Non-primary (AL) amyloidosis (ICD-9-CM code 277.3), effective 10/01/00; or
- o Primary (AL) amyloidosis (ICD-9-CM code 277.3) for Medicare beneficiaries age 64 or older, **effective 10/01/00.**
- **NOTE**: Coverage for conditions other than these specifically designated as covered or noncovered in this section or §35-30.1 of the CIM is left to the intermediary's discretion.
- D. <u>Billing for Autologous Stem Cell Transplants</u>.--Since there are no covered acquisition charges for autologous stem cell transplants, all charges are shown in the usual manner. Charges for the transplant itself are shown in revenue center code 362 or other appropriate cost center.
- 3614.3 <u>Acquisition Costs.</u>—Stem cell acquisition charges are identified separately in FL 42 of Form HCFA-1450 by using revenue codes 819 (Other Organ Acquisition) and/or 891 (Other Donor Bank, Bone). Do not make separate payment for these acquisition charges as payment is included in the DRG payment.
- For allogeneic stem cell transplants (procedure codes 41.02, 41.03, 41.05, or 41.08), where interim bills are submitted, the acquisition charge appears on the billing form for the period during which the transplant took place. Since claims for stem cell transplants are paid using PPS, process an adjustment bill to recover payment if you have already paid the interim bill. Where no interim bills are involved, all charges appear on the transplant bill.

The transplant hospital keeps an itemized statement that identifies the services furnished, the charges, the person receiving the service (donor/recipient), and whether this is a potential transplant donor or recipient. These charges are reflected in the transplant hospital's stem cell/bone marrow acquisition cost center. Include charges for all services required in acquisition of stem cells, i.e., tissue typing and post-operative evaluation, in revenue codes 819 and 891.

- For allogeneic stem cell transplants (procedure codes 41.02, 41.03, 41.05, or 41.08), charges for acquisition and any applicable storage charges will appear on the recipient's transplant bill. Acquisition charges do not apply to autologous stem cell acquisitions. The charges, cost report days, and utilization days for the stay in which the stem cells were obtained are reported on the transplant bill.
- 3614.4 Notifying Carriers.--Carriers will automatically be notified via a CWF trailer.

Rev.1805 6-136.5